pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,959 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1032Endpoints785BioPharma Dive299BioSpace219Fierce Biotech207onclive165raps78globenewswire health
therapy area
allOncology6110Rare Disease1467Cardiology1094Hematology1031Immunology1020Vaccines919Pulmonology
  • Ambient scribing startups draw attention as Abridge secures $300 million funding
    Last summer, a wave of ambient scribing startups captured the health-tech spotlight. These companies employ artificial-intelligence systems that listen to doctor-patient conversations and automati…
    Endpoints · 18d agoDealNeutral↗ source
  • UK regulator debates whether AI scribes count as medical devices
    UK regulators are examining whether AI-driven clinical documentation tools, often called AI scribes, should be classified as medical devices under current law. The proposal has generated debate am…
    STAT · 18d agoRegulatoryNeutral↗ source
← prev
page 15 of 79
next →
73
fda recalls48
fda medwatch41
fda press28
911
Psychiatry & CNS727
Ophthalmology425
Pain406
Endocrinology & Metabolism390
Infectious Disease362
  • Akido expands AI-driven patient intake and diagnostic tools to 100 clinics
    Akido, a health‑technology startup, announced it will deploy its artificial‑intelligence platform for patient intake and diagnostic assistance in 100 clinics. The AI system captures patient inform…
    Endpoints · 18d agoDealPositive↗ source
  • Analysis questions expanded orphan drug exemptions under recent legislation
    Ed Silverman, a Pharmalot columnist, examined a provision in the One Big Beautiful Bill Act that keeps certain orphan drugs out of Medicare price negotiations. The Inflation Reduction Act, which b…
    STAT · 18d agoRegulatoryNegative↗ source
  • Bayer plans German launch of new stroke drug despite healthcare spending cuts
    Bayer announced it will move forward with the launch of its new stroke medication in Germany. The decision comes even though Germany has introduced a new healthcare spending bill that reduces reim…
    Endpoints · 18d agoNeutral↗ source
  • Merck's anti-TL1A antibody shows benefit in hidradenitis suppurativa but misses endpoint in rare lung disease trial
    Merck reported mixed results from its anti‑TL1A antibody, a product of its $10.8 billion acquisition of Prometheus Biosciences. In a mid‑stage study for hidradenitis suppurativa, the antibody met…
    Endpoints · 18d agoNeutral↗ source
  • AstraZeneca and Bristol Myers Squibb rumored to be in talks for a major merger
    Over the weekend, reports emerged that AstraZeneca and Bristol Myers Squibb were reportedly discussing a possible merger. Industry observers note that such a combination would create one of the la…
    Endpoints · 18d agoDealNeutral↗ source
  • Kennedy and Oz dismiss Medicaid cut claims, but state officials warn new rules could strip coverage
    Health secretary Robert F. Kennedy Jr. and former Vice President Dan Oz asserted that the administration is not cutting Medicaid, calling the idea a myth during a farm visit in Michigan. State Med…
    STAT · 18d agoRegulatoryNegative↗ source
  • Merck to test experimental sac-TMT antibody-drug conjugate with Keytruda in lung cancer trial
    Merck announced it will start a clinical trial testing its experimental antibody-drug conjugate sac-TMT together with the immunotherapy Keytruda in patients with lung cancer. The study will assess…
    Endpoints · 18d agoNeutral↗ source
  • Eli Lilly expands early-access program for experimental obesity drug retatrutide
    Eli Lilly announced it will broaden its early-access initiative for retatrutide, an investigational drug targeting obesity. The company said the program will let additional patients apply for the…
    STAT · 18d agoRegulatoryPositive↗ source
  • Pfizer adds $2.5 billion to cost-cutting plan, pushing total savings past $10 billion
    Pfizer announced on Tuesday an additional $2.5 billion of cost reductions across the company, extending its multi-year austerity program. The new cuts bring the cumulative savings effort to more t…
    Endpoints · 18d agoNegative↗ source
  • US-China biotech rivalry sparks calls for deeper discussion, says editor
    The editor notes that the ongoing debate over the competitive relationship between U.S. and Chinese biotechnology sectors has been unfolding over recent months. While many knowledgeable voices are…
    Endpoints · 18d agoNegative↗ source
  • Aurora Therapeutics halts its custom CRISPR program and cuts staff after competitor Beam moves ahead
    Aurora Therapeutics, a startup developing personalized gene-editing drugs, announced it is abandoning its lead CRISPR program. The decision came just seven months after the company launched, and i…
    STAT · 18d agoLayoffsNegative↗ source
  • Early Alert: Intraosseous Needle Set Issue from Becton Dickinson
    BD is recalling certain BD Intraosseous Vascular Access System Needle Sets due to difficulty removing the obturator (stylet) following placement.
    fda medwatch · 18d agoRegulatoryNeutral↗ source
  • Amgen drops early-stage obesity drug candidate AMG-513
    Amgen announced it is discontinuing its early-stage obesity candidate AMG-513. The program was in Phase 1, but the company provided no details about the study or the reasons for the halt. A spokes…
    Endpoints · 18d agoNegative↗ source
  • Two Michigan Cyclospora Deaths Reported as Eli Lilly Expands Special Retatrutide Access
    Two people in Michigan have died after contracting cyclospora, a parasitic infection that is rarely fatal but can be severe for those with underlying health conditions. State health officials confi…
    STAT · 18d agoRegulatoryNeutral↗ source
  • Patient finds open-source diabetes app improves control despite lack of FDA approval
    Patient has type 1 diabetes for over 30 years and has used FDA-approved pumps and sensors that were upgraded roughly every five years. Over time his glucose control slipped despite the regulated de…
    STAT · 18d agoPositive↗ source
  • Liebel-Flarsheim recalls OPTIRAY imaging contrast agent after detecting plastic, metal and glass particles
    Liebel-Flarsheim Company announced a recall of one lot of its OPTIRAY Imaging Bulk Package, a 350/500 mL vial of ioversol injection used for intra‑arterial and intravenous imaging. The recall was…
    fda medwatch · 18d agoCRLNegative↗ source
  • Danske Bank reports share sale by APMH Invest under its buyback program
    On August 4, 2026, Danske Bank A/S filed a market‑abuse regulation report detailing a change in share ownership. The filing shows that APMH Invest A/S sold a portion of its Danske Bank shares on a…
    globenewswire health · 18d agoRegulatoryNeutral↗ source
  • Novo vs. Lilly: Q2's cardiometabolic grudge match
    For years, Novo Nordisk and Eli Lilly have dominated the conversation surrounding obesity medicines as the duopoly competes to lead the largest pharmaceutical category in history. While dozens of c…
    Endpoints · 18d agoNeutral↗ source
  • Danske Bank discloses managerial transactions per Danish regulator on Aug 4, 2026
    Danske Bank A/S issued a notification on 4 August 2026 regarding transactions made by individuals who hold managerial responsibilities. The disclosure follows the EU Market Abuse Regulation, requi…
    globenewswire health · 18d agoRegulatoryNeutral↗ source
  • New York study questions effectiveness of involuntary outpatient mental health treatment, urges more funding for voluntary services
    A new evaluation of New York's involuntary outpatient treatment program adds to a growing body of research on court‑ordered mental health care. The study examined outcomes for people with serious c…
    STAT · 18d agoNegative↗ source
  • Danske Bank reports ongoing share buy-back related sales by APMH Invest
    Danske Bank A/S filed a notification on 4 August 2026 concerning transactions made by persons with managerial responsibilities. The filing, identified as notification no. 61/2026, complies with th…
    globenewswire health · 18d agoRegulatoryNeutral↗ source
  • Danske Bank reports ongoing share buy-back and manager-related share sales
    Danske Bank A/S disclosed that, as part of its share repurchase programme, APMH Invest A/S is continuously selling shares on a proportional basis. The filing notes that the transactions are made b…
    globenewswire health · 18d agoRegulatoryNeutral↗ source
  • Danske Bank files mandatory disclosure of manager transactions under EU market abuse rules
    Danske Bank A/S submitted a notification on 4 August 2026 detailing transactions made by individuals with managerial responsibilities, as required by the Danish Financial Supervisory Authority and…
    globenewswire health · 18d agoRegulatoryNeutral↗ source